A Phase 1/2 Study of EG-70 as an Intravesical Administration to Patients With BCG Unresponsive Non-Muscle Invasive Bladder Cancer (NMIBC) and High-Risk NMIBC Patients Who Are BCG Naïve or Received Incomplete BCG Treatment
This study is testing a new experimental medicine called EG-70 for people with early-stage bladder cancer that has not spread into the muscle wall. Researchers want to see if placing this medicine directly into the bladder is safe and helps fight the cancer, especially for patients whose previous treatments did not work.
You may be able to join if you have early-stage bladder cancer that has not spread to the muscle wall and your cancer did not respond well to standard BCG immunotherapy. Some groups who have never received BCG or received incomplete treatment may also qualify, as long as you meet certain health and treatment history requirements.
Participants will receive the study drug, EG-70, placed directly into the bladder through a small tube. Some patients might also receive a special liquid wash in the bladder right before getting the study medicine. Doctors will monitor your health closely throughout the study to check for safety and effectiveness.
This study is currently recruiting patients at medical centers in locations such as Birmingham, Alabama, and Scottsdale and Tucson, Arizona. More locations may be available, so your care team can help you find the closest spot.
- 1Testing a new bladder cancer treatment called EG-70
- 2Open to patients with early-stage bladder cancer that has not spread to the muscle
- 3Currently recruiting participants at select locations in the United States
Related video
Related links
Outside pages about this study, checked by our team
This summary was generated using AI and may not capture all details. Always consult with a healthcare professional for medical advice.